Literature DB >> 8783810

Quinolone-induced cartilage lesions are not reversible in rats.

C Förster1, K Kociok, M Shakibaei, H J Merker, R Stahlmann.   

Abstract

The reversibility of quinolone-induced cartilage lesions has not been studied in detail. We treated five groups of five to seven juvenile Wistar rats (male and female; age: 5 weeks) with 2 x 600 mg ofloxacin/kg by gastric intubation on 1 day only (9:00 a.m. and 5:00 p.m.) and studied the knee joints histologically 3 days, 1, 3, 8 and 17 weeks later. In addition, joint cartilage specimens from vehicle-treated control rats (n = 21) at corresponding age were examined. Cartilage lesions such as matrix swelling, loss of proteoglycans and horizontal clefts were found in nearly all knee joints (26 of 27 joints; incidence: 96%) of the ofloxacin-treated rats. Within the observation period of 4 months the size of these lesions in knee joint cartilage did not decrease significantly. The diameter of the lesions at the time points of evaluation was 1146 +/- 535, 1713 +/- 309, 1250 +/- 585, 1406 +/- 356, and 1542 +/- 467 microns, respectively (mean values +/- sd). Chondrocyte clusters producing glycosaminoglycans were observed 3 weeks after dosing and at later time points. They are considered to reflect the onset of repair but chondrocyte organization did not normalize during the study period, thus indicating the irreversibility of the effect under the experimental conditions. In principle, long-term joint cartilage damage has to be taken into account when the use of quinolones in children is considered. More detailed pharmacokinetic data are necessary for a reasonable risk assessment approach.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8783810     DOI: 10.1007/s002040050301

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  9 in total

1.  Diminished ciprofloxacin-induced chondrotoxicity by supplementation with magnesium and vitamin E in immature rats.

Authors:  Kerstin Pfister; Dago Mazur; Jürgen Vormann; Ralf Stahlmann
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

Review 2.  Safety considerations of fluoroquinolones in the elderly: an update.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

3.  Proteoglycan and collagen biochemical variations during fluoroquinolone-induced chondrotoxicity in mice.

Authors:  M A Simonin; P Gegout-Pottie; A Minn; P Gillet; P Netter; B Terlain
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 4.  Toxicity of quinolones.

Authors:  R Stahlmann; H Lode
Journal:  Drugs       Date:  1999       Impact factor: 9.546

5.  Results of a Multicenter Population Pharmacokinetic Study of Ciprofloxacin in Children with Complicated Urinary Tract Infection.

Authors:  Kevin Meesters; Robin Michelet; Reiner Mauel; Ann Raes; Jan Van Bocxlaer; Johan Vande Walle; An Vermeulen
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

Review 6.  Fluoroquinolones in the elderly: safety considerations.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Comparative effects of systemic administration of levofloxacin and cephalexin on fracture healing in rats.

Authors:  Shayan Golestani; Arash Golestaneh; Atousa Aminzadeh Gohari
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2022-04-30

Review 8.  Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.

Authors:  Aparna Mukherjee; Rakesh Lodha; Sushil Kumar Kabra
Journal:  Expert Opin Pharmacother       Date:  2017-10-09       Impact factor: 3.889

9.  Systemic fluoroquinolone prescriptions for hospitalized children in Belgium, results of a multicenter retrospective drug utilization study.

Authors:  Kevin Meesters; Reiner Mauel; Evelyn Dhont; Johan Vande Walle; Pauline De Bruyne
Journal:  BMC Infect Dis       Date:  2018-02-23       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.